ResearcherHenan UniversityActive in the last 2 years
Sung Yong Choi
Matched on ORCID iD 0000-0002-4865-5677; OpenAlex author ID A5101917897. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 2
- Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Co-author DOI 10.1111/cas.16104↗
- Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Sam… Co-author DOI 10.3389/fonc.2019.00875↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sung‐Sik Han · 2 shared papers, 2019–2024 · strength 0.27
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Mo… DOI 10.3389/fonc.2019.00875↗
- Min Kyeong Kim · 2 shared papers, 2019–2024 · strength 0.27
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Mo… DOI 10.3389/fonc.2019.00875↗
- Kyong‐Ah Yoon · 2 shared papers, 2019–2024 · strength 0.27
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Mo… DOI 10.3389/fonc.2019.00875↗
- Woo Jin Lee · 2 shared papers, 2019–2024 · strength 0.27
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Mo… DOI 10.3389/fonc.2019.00875↗
- Sang‐Jae Park · 2 shared papers, 2019–2024 · strength 0.27
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Mo… DOI 10.3389/fonc.2019.00875↗
- Sun‐Young Kong · 2 shared papers, 2019–2024 · strength 0.27
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Mo… DOI 10.3389/fonc.2019.00875↗
- Yun‐Hee Kim · 2 shared papers, 2019–2024 · strength 0.27
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Mo… DOI 10.3389/fonc.2019.00875↗
- Sang Myung Woo · 2 shared papers, 2019–2024 · strength 0.27
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Mo… DOI 10.3389/fonc.2019.00875↗
- Mi Rim Lee · 1 shared paper, 2024 · strength 0.19
- Jung Won Chun · 1 shared paper, 2024 · strength 0.19
- Yu‐Sun Lee · 1 shared paper, 2019 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.